Skip to main content

Research with a destination | A question to investigate

What changes when a cell refuses to stay the same?

A disease can look different when examined as a changing population of cells rather than a single fixed category. Our biological research interest is in the questions that follow: how states emerge, persist and influence the next experiment.

Begin with a precise biological uncertainty.

Treatment resistance can invite sweeping explanations. A useful research proposal needs a narrower question, such as whether an observed cell state is stable under a defined condition or whether a signal reflects a change in composition. GLIO is one aspect of NEUVIOR's wider biological research interest. We want discussions that begin with a testable uncertainty and a model suited to it, rather than treating a broad disease label as an experimental plan.

Keep the model attached to the finding.

A result from a cell line, an organoid, animal tissue or human material has a specific context. Each can help answer some questions and leave others open. The proposed inputs would include the model's provenance, relevant characterisation, experimental conditions and known limitations. An attractive microscopy image should lead a reader towards that context. It cannot establish that the same pattern exists in people or that a treatment will work in a clinical setting.

Separate observation from mechanism.

Two markers appearing together may suggest a useful next question, but observation alone does not explain why the pattern occurs. A proposed collaboration could combine a descriptive analysis with a carefully chosen perturbation or independent measurement, if justified by the model and permissions. The comparator would be a relevant control under matched conditions. We would agree what outcome would support the mechanism, what would weaken it and what would remain unresolved despite a positive signal.

A dependency belongs to a defined experimental state

Published response curves sit beside genetic perturbation, microscopy and slice-culture measurements. Their combination makes the proposed collaboration question specific: which state was affected, under which conditions, and what further comparison could challenge the explanation?

Full Banu Figure 4 with response curves, perturbation measurements and fluorescence microscopy of experimental glioma slice cultures.

External preclinical research: Banu et al. (2024), Figure 4, examines differential GPX4-related sensitivity in the authors’ experimental glioma systems. All original panels and labels remain visible. These are published external results, not a NEUVIOR experiment, clinical therapeutic window or treatment recommendation.

Banu, Matei A; Dovas, Athanassios; Argenziano, Michael G; Zhao, Wenting; Sperring, Colin P; Cuervo Grajal, Henar; Liu, Zhouzerui; Higgins, Dominique MO; Amini, Misha; Pereira, Brianna; Ye, Ling F; Mahajan, Aayushi; Humala, Nelson; Furnari, Julia L; Upadhyayula, Pavan S; Zandkarimi, Fereshteh; Nguyen, Trang TT; Teasley, Damian; Wu, Peter B; Hai, Li; Karan, Charles; Dowdy, Tyrone; Razavilar, Aida; Siegelin, Markus D; Kitajewski, Jan; Larion, Mioara; Bruce, Jeffrey N; Stockwell, Brent R; Sims, Peter A; Canoll, Peter · A dependency belongs to a defined experimental stateCC BY 4.0 | Inspect the complete figure

Source and image notes

Faithful proportional viewing copy in WebP; complete original figure and all panels retained. No crop, colour adjustment, relabelling, animation or added data.

For biological research collaborators

Would changing this cell state change the outcome?

Compare two ways of interpreting a cell-state observation: describing the cells present and testing whether changing them alters later behaviour. The fork separates a matched control from a proposed perturbation, while shared identity checks keep both branches attached to the same model. These are design choices for a possible study, not experimental findings.

Scientists considering a model-specific cell-state collaboration

Editorial decision model, not measured NEUVIOR results. The fork depicts proposed comparison logic, not a demonstrated causal pathway. Positions and sizes are schematic. External research retains its original model limits; this record establishes no authorised study, experimental capability or treatment benefit.

A clearer description can still leave causality open.

This lens asks whether the observed population has been identified convincingly and whether its apparent change could arise from composition. Better identity evidence can strengthen the description, but it does not show that the state causes resistance or later regrowth. The next study may still need a discriminating intervention.

Write the strongest model-specific descriptive conclusion, then name the causal claim it cannot support.

A causal comparison must survive alternative explanations.

This lens follows the two branches into the same behavioural readout. A useful perturbation comparison would distinguish the proposed mechanism from handling effects, lost cell identity or general toxicity. Even a supportive finding remains bounded by the model, measurement and observation period rather than establishing a clinical treatment effect.

Specify one control or independent measurement that could overturn the preferred mechanism.

In focus

Model and history

The same marker pattern can carry different meanings in a cell line, organoid or tissue sample. A proposed comparison would begin with provenance, treatment history and culture conditions, so the model constrains every explanation that follows.

  • History constrains the state interpretation
Evidence to keep in view

Model provenance, material permissions, characterisation and the conditions preceding the observation.

A useful next step

Which features of the intended biological question does this model reproduce, and which are absent?

A collaboration becomes more informative when its control, perturbation and identity checks can distinguish the explanation that would change the next experiment.

A dividing cell changes its organisation in time

Cell state is not a static label. This published MDCK time-lapse lets collaborators inspect how division and membrane organisation unfold together, then ask which observations distinguish a changing organisation from selection of a different population.

Published MDCK-cell imaging of labelled Rab35 and podocalyxin during division in Matrigel. MDCK is an epithelial model; this is not glioblastoma footage or a demonstrated NEUVIOR mechanism.

Klinkert K, Rocancourt M, Houdusse A, Echard A · A dividing cell changes its organisation in timeCC BY 4.0 | Original research and methods

Source and image notes

H.264 viewing copy; complete frame retained with proportional downscaling where required; no colour enhancement, crop, speed change or added frames. Audio omitted; original source remains linked.

Follow the labelled structures

Reporter location changes during division; identify the cell and acquisition interval before interpreting that motion.

Keep the lineage question open

A time-lapse can connect observations within one lineage, but additional evidence is needed to infer a stable state or causal mechanism.

A published example with its model left attached.

Banu and colleagues (2024) compared genetically engineered murine gliomas with and without activated Notch signalling. Their Figure 1 distinguishes astrocyte-like transformed cells from other tumour-associated cells, showing why marker identity and experimental model matter when interpreting an image. This is external published research, not a NEUVIOR result or evidence of a treatment benefit in people. The example gives a collaborator a concrete question: can the chosen measurement distinguish the cell population the experiment is intended to study? Banu et al. | The EMBO Journal (2024)

A sample experiment-decision sheet.

The first deliverable could place the biological question beside competing explanations, the chosen model, its identity checks and the control needed to distinguish those explanations. It would name the proposed measurement and show how a negative or ambiguous result changes the next experiment. A collaborator should be able to challenge the inference before committing material or instrument time. That makes the sheet a practical choice about the next experiment, rather than a catalogue of attractive methods.

Continue at experimental decision gates.

The appropriate cadence is the point before a new experimental series, and again when interpretable findings justify changing it. An academic or industrial sponsor would bring model provenance, material rights, the available methods and a scientist responsible for the question. Acceptance would require agreement that the comparison can distinguish the competing explanations within the model’s limits. Further work would depend on that decision and the relevant facilities and permissions, rather than an assumed monthly research service.

Design for variation rather than hiding it.

Batch, timing, handling and analysis choices can change what an experiment appears to show. We propose documenting these influences and deciding in advance how repeated measurements and exclusions will be handled. A result should not depend on selecting the most striking field of view. The initial output could be a model-specific evidence map and an experimental design, with enough detail for an independent collaborator to assess whether the planned comparison is capable of answering the question.

Choose methods with responsibility built in.

NC3Rs' 3Rs principles inform the consideration of alternatives and responsible model choice (NC3Rs, n.d.). ARRIVE provides reporting guidance where animal research is relevant (NC3Rs, n.d.). These references do not imply that NEUVIOR has an authorised animal study or a laboratory delivering one. Any proposed work would require the appropriate sponsor, expertise, approvals, facilities and material rights. Where existing or non-animal approaches can answer the question well, they should be considered before a new animal experiment.

Value an answer that changes the programme.

A valuable result might rule out a weak mechanism, identify the conditions under which a state appears or show that an analytical method is insufficiently specific. Those findings can direct resources towards a stronger experiment. The commercial relevance would depend on a later application and evidence path, assessed separately. We would not convert a promising biological observation into a product claim, patient benefit or treatment recommendation simply because the underlying question is important.

A first collaboration should earn the second.

The bounded next step is a discussion around one model, one state-related question and one credible comparison. The proposed deliverable is a protocol and feasibility assessment before experimental work is committed. We would pause if model provenance is unclear, the available method cannot distinguish the competing explanations or the experiment would overreach its permissions and resources. Continuation should rest on interpretable evidence and an agreed next decision, with negative findings preserved alongside positive ones.

Sources and context

NC3Rs (n.d.) The 3Rs. Available at: https://nc3rs.org.uk/who-we-are/3rs (Accessed: 14 October 2026).

NC3Rs (n.d.) ARRIVE guidelines 2.0. Available at: https://arriveguidelines.org/arrive-guidelines (Accessed: 14 October 2026).

Another useful angle.

  • Formulation feasibility research

    Explore early formulation questions around stability, measurement and reproducibility, with a defined comparator and evidence needed for a development decision.

  • Academic and commercial translation

    Connect an academic finding with a credible user, comparator and next experiment, while keeping research rights and commercial translation questions clear.

  • Industrial measurement research

    Examine whether an industrial measurement can support a medicines process decision, including reference methods, uncertainty, operating conditions and full effort.

NEWSPerspectives & features